Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers
Clinical trial NCT02273531 · COMPLETED
Trial details
- NCT number
- NCT02273531
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2004-01-01
- Primary completion
- 2004-03-01
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.